###### Key messages

What is already known about this subject?
=========================================

-   Spondyloarthritis leads to healthcare costs as well as productivity loss, the latter having been shown to be the most significant cost driver. However, there is a lack of cost-of-illness studies among patients with early SpA in the biologics era.

What does this study add?
=========================

-   In the biologic era, medication is the greatest cost driver among patients with SpA, exceeding productivity loss. Other factors like age, peripheral arthritis and functional ability are independently associated with total costs. In a cohort of patients with early SpA using biologics for less than 3 years, biologic use was associated with increased costs outside of biologics.

How might this impact on clinical practice?
===========================================

-   This study identifies factors associated with SpA-related costs in the biologic era, potentially pointing towards priority areas for biologics use and providing a new benchmark for cost of illness among patients with early SpA.

Introduction {#s1}
============

Spondyloarthritis (SpA) is a family of chronic rheumatic diseases that includes ankylosing spondylitis (AS), psoriatic spondyloarthritis (PsA), reactive SpA, SpA with inflammatory bowel disease and undifferentiated SpA.[@R1] In its early phases, SpA is often undifferentiated, and corresponds to the concept of inflammatory back pain (IBP), the key feature of the disease.[@R2] To date, most economic studies of SpA have examined outcomes among patients with AS or PsA specifically, and have not included patients with other SpA subtypes or with early SpA symptoms that are still evolving. A severe form of SpA, AS has been shown to cause significant pain, functional disability and loss of mobility[@R3] In turn, these physical outcomes are associated with substantial health resource utilisation and work productivity loss among patients with AS.[@R4] [@R5]

In 2012, a systematic review identified 15 economic studies of SpA conducted worldwide since 2002, nine of which evaluated health resource utilisation and work productivity loss. The median cost of health resource utilisation in 2012 US dollars was \$3764 per patient per year, compared to a median cost of productivity loss of \$4999.[@R6] More recently, biological TNF blockers have been made available for the treatment of moderate to severe SpA, increasing the cost of illness compared to previous years in which non-steroidal anti-inflammatory drugs (NSAIDs) were the only available drug therapy.[@R7]

The objective of this study was to value health resource utilisation and productivity losses among patients in the DESIR cohort,[@R8] a longitudinal, multicentre study of early SpA in France. We further aimed to determine factors associated with total costs and with costs excluding biologics ('non-biologic costs') among DESIR patients.

Methods {#s2}
=======

Participants {#s2a}
------------

The DESIR cohort[@R9] includes 708 patients aged 18--50 with early IBP lasting more than 3 months but less than 3 years, and suggestive of SpA according to the rheumatologists\' assessment (score ≥5 on a 0--10 Numerical Rating Scale where 0=not suggestive and 10=very suggestive). Patients were required to fulfil the Calin[@R10] or Berlin[@R11] IBP criteria. Patients with a definitive diagnosis of non-SpA back pain, a history of previous biological TNF-blocker use, or conditions that could affect informed consent and/or compliance (eg, alcoholism, psychiatric disorders) were excluded. All patients attended their baseline study visit between October 2007 and May 2010. Follow-up visits collecting self-report questionnaire data occurred every 6 months in the first 2 years and every year thereafter, and covered the health resource use since the previous visit. Our analyses included the first 3 years of follow-up, that is, baseline plus follow-up visits at months 6, 12, 18, 24, 36. Data up to month 12 were from the DESIR database locked in February 2014, and data from months 18 to 36 from that locked in April 2015.

Costing methods {#s2b}
---------------

Our analysis estimated the total cost from the societal perspective (all payers combined) of all-cause health resource utilisation, specifically health practitioner visits, hospitalisations (including emergency room visits and surgeries), medical workups, and medications), and work productivity losses. Although we aimed to include as many societal costs as possible, other patient out-of-pocket costs (eg, transportation, devices, caregiver expenses and other costs sometimes termed 'non-medical') were not included.

### Valuing health resource use {#s2b1}

Detailed costing methods are described in online [supplementary tables S1--S4](#SM1){ref-type="supplementary-material"}. Unit costs for health practitioner visits were estimated by adding base tariffs from the French National Health Insurance[@R12] to the average cost of extra billings based on data from the IRDES (Institut de Recherche et de Documentation en Economie de la Santé)[@R13] Eco-Santé database.[@R14] Data on medical workups included laboratory analyses on blood and urine and functional/diagnostic tests. On the basis of clinical expertise, the cost of blood tests was estimated assuming the following standard laboratory analyses among patients with SpA: erythrocyte sedimentation rate (ESR); C-reactive protein (CRP); haemogram including platelets; thrombocytes; transaminases; creatinine; and creatinine clearance. Blood collection was valued at 15 min of nurse care; the unit cost of blood tests was the cost of analysis plus the cost of collection as per the French public insurance fee schedule. Urine tests were assumed to include urine protein only and no collection fee was applied. The following tests were attributed a single standard cost: mammography, MRI, bone densitometry, scintigraphy, respirometry, colonoscopy and fibroscopy. For X-rays, ultrasounds, scans and 'other exams', free-text data were reviewed individually and assigned specific examination codes which were linked to unit costs.
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Data on medications included NSAIDs, DMARDs (conventional synthetic---csDMARDs---or biologic---bDMARD), corticosteroids (oral, intramuscular, intra-articular and intravenous) and analgesics. For abatacept, infliximab and certolizumab, prices per milligram were derived from list prices in France using the Vidal dictionary.[@R15] For all other drugs, cost data from the French public drug program[@R16] were used to derive a price per milligram for each drug. Drugs were valued by multiplying price per milligram by number of milligrams per day by number of days of use (except injectable corticoids, which were valued by multiplying price per milligram by number of milligrams in the reported number of injections). Where dose data were missing, standard dosages were imputed taking into account the patient\'s weight where applicable. For infliximab only, a standard cost for administration in day hospital was applied every 6 weeks for the duration of the therapy.

Data on hospitalisations were assigned a diagnosis or act code and linked to Diagnosis-Related Group (DRG) codes using 2012 data from the French national agency for hospital information (ATIH, 'Agence Technique de l\'Information sur l\'Hospitalisation').[@R17] Selected DRG were then linked to costs using 2012 ATIH data.[@R18] The base-case analysis used the 6-digit DRG selected as the best fit; sensitivity analyses were performed using DRG sharing the same first five digits as the best-fit DRG (see online [supplementary table](#SM1){ref-type="supplementary-material"} S3). All unit costs were adjusted to 2013 Euros based on the Consumer Price Index[@R19] and multiplied by frequency of use.

### Valuing work productivity loss {#s2b2}

Data on patients\' profession were collected in eight categories ([table 1](#RMDOPEN2015000230TB1){ref-type="table"}). Average daily wage data were obtained from the French Ministry of Agriculture[@R20] and from the French National Institute of Statistics and Economic Studies ('INSEE').[@R20] Productivity loss was valued by multiplying the number of self-reported workdays lost per period by the average daily wage by professional category over the entire population of French workers as estimated by these public data sources. The age and sex distribution of the DESIR cohort was compared to that of the population of French workers from which average daily wages were obtained and wages were not further adjusted for age and sex.

###### 

Baseline characteristics of the DESIR cohort

                                                        All (n=708)   
  ----------------------------------------------------- ------------- ------
  Age, sex, ethnicity                                                 
   Age group \<25                                       133           18.8
   Age group ≥25 and \<55                               572           80.1
   Age group ≥50                                        3             0.4
   Male                                                 327           46.2
   Caucasian                                            634           89.6
  Highest level of education                                          
   High school or less                                  286           40.4
   Post-secondary school                                418           59
  Profession\*                                                        
   Agriculturer                                         6             0.9
   Artisan, retailer or small business owner            35            4.9
   Executive or academic                                151           21.3
   Intermediate professional                            54            7.7
   Employee                                             299           42.6
   Tradesperson                                         64            9
   Without professional occupation                      93            13.3
  Clinical characteristics                                            
   Early onset (\<17 years)                             13            1.8
   Late onset (\>44 years)                              72            10.2
   *Presence of extra-articular manifestations*         188           26.6
    Uveitis                                             60            8.5
    Psoriasis                                           112           15.8
    Crohn\'s disease                                    18            2.5
   HLA B27 positive                                     410           57.9
   ASAS criteria (total): positive                      486           68.6
   ASAS clinical criteria: positive                     404           57.1
   ASAS imaging criteria: positive                      286           40.4
  Clinical values                                       Mean          SD
  Disease duration in years                             1.5           0.9
  Physician\'s assessment of disease activity (0--10)   4.3           2.2
  BASDAI score (0--100)                                 44.7          20
  BASFI score (0--100)                                  30.4          22.8

\*Per cent values do not total 100 due to missing baseline data.

ASAS, the Assessment of SpondyloArthritis international Society.

### Handling missing clinical and cost data {#s2b3}

Missing cost and clinical data were imputed using the Monte Carlo Markov Chain (MCMC) multiple imputation procedure, the last observation carried forward (LOCF) method, probabilistic imputation, or with negative values based on clinical expertise. Specifically, for clinical variables in which fluctuations are normal and commonly observed clinically (ie, ASDAS-CRP, BASDAI, BASFI and HAQ), missing data were handled with MCMC imputation, which was considered the best strategy for representing this variability. For clinical variables observed to have greater stability, either the LOCF method or probabilistic imputation was used in lieu of MCMC imputation, as these methods provide better control over the variability of values imputed; LOCF was used if all patients had baseline data, while probabilistic imputation was used if baseline data were missing. The imputation model is described in detail in the online [supplementary appendix](#SM2){ref-type="supplementary-material"}.
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### Statistical analyses {#s2b4}

Patient characteristics were described by the mean±SD or number (%) at baseline. For descriptive purposes, patients were divided into four subsets based on imaging status: X-ray damage only; MRI inflammation only; X-Ray damage and MRI inflammation; neither. Costs of health resource utilisation and productivity losses were expressed as yearly costs. For health resource utilisation, year 1 costs were the sum of costs reported at months 6 and 12; year 2 costs were the sum of costs reported at months 18 and 24; year 3 costs were those reported at month 36. For productivity losses, yearly costs were those reported at the 12-month, 24-month and 36-month visits. Yearly costs were described by the median and mean±SD.

To describe factors associated with annual total costs and non-biologic costs over the 3 years, we used generalised linear models with a γ distribution of log link and a generalised estimating equations algorithm to account for repeated measures within participants. The independent variables year, baseline age and sex were chosen to be included in all models throughout development. Other independent variables of interest included baseline education; profession; presence of peripheral arthritis at baseline; DESIR study centre; number of months on biologics; baseline imaging status; baseline BASDAI and BASFI values; and mean BASDAI and BASFI values (where year 1 mean=mean of months 0, 6, 12; year 2 mean=mean of months 12, 18, 24; and year 3 mean=mean of months 24, 36). At the outset, baseline and mean BASDAI and BASFI values were tested for collinearity and examined alone and together in models. Goodness of fit assessed by the quasi-likelihood statistic (QIC) was used to compare the model fit among models with various BASDAI and BASFI values (baseline, mean, or baseline and mean together).[@R21] The model with the best fit was chosen for inclusion in subsequent models. All other independent variables of interest were examined separately in models adjusting for year, age and sex, and variables associated with the outcome at p\<0.20 were selected for inclusion in subsequent models. Model selection was then done in a backward stepwise manner, beginning with all variables and removing those that were not associated with the outcome at p\<0.05 to increase goodness of fit based on the QIC. All analyses were performed using SAS 9.4.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

At baseline, the mean age of patients was 33.7±8.6 years and mean disease duration was 1.5±0.8 years. Just under half of the patients were male (46.2%) and the majority were Caucasian (89.6%) ([table 1](#RMDOPEN2015000230TB1){ref-type="table"}). Most patients were HLA-B27-positive (57.9%). The mean BASDAI score (on 100) at baseline was 44.7±20.0 and the mean BASFI score was 30.5±22.8. The most common extrarheumatological manifestations were psoriasis (15.8%) and uveitis (8.5%). At baseline, 286 patients satisfied the Assessment of SpondyloArthritis international Society (ASAS imaging criteria (40.4%) and 404 the ASAS clinical criteria (57.1%); 486 patients satisfied one or the other (68.6%). [Table 1](#RMDOPEN2015000230TB1){ref-type="table"} shows the characteristics of patients by imaging status, that is, X-ray damage alone (7.2%), MRI inflammation (13.8%); X-ray damage and MRI inflammation (18.6%), neither (56.9%); a total of 24 patients had no data available to describe imaging status. Attendance at follow-up visits declined over time: of the 708 patients enrolled at baseline, 704 attended the 6-month visit, 698 the 12-month visit, 691 the 18-month visit, 692 the 24-month visit, and 631 the 36-month visit.

Costs {#s3b}
-----

### Health resource utilisation {#s3b1}

[Table 2](#RMDOPEN2015000230TB2){ref-type="table"} shows the estimated costs of health resource utilisation and productivity losses among all DESIR patients over 3 years. Medication was the largest cost component in all years, representing over 50% of all costs in all years. The absolute mean cost of medication increased from €2680.2±5339.6 in year 1 to €3339.2±6224.1 in year 2 to €3396.3±6476.5 in year 3. The proportion of patients incurring costs from biologics was approximately a quarter each year. The cost of biologics accounted for approximately 95% of medication costs each year.

###### 

Cost components as proportion of total costs by year of follow-up and biologics use

  Patient group                       Cost component                  Year 1 (%)   Year 2 (%)   Year 3 (%)   Three-year total (%)
  ----------------------------------- ------------------------------- ------------ ------------ ------------ ----------------------
  All patients (n=708)                Health practitioners            15           11           10           12
                                      Medical workups                 5            4            3            4
                                      Hospitalisations                10           10           9            9
                                      Biologics                       50           59           66           58
                                      All drugs                       54           61           68           61
                                      Productivity loss               17           14           10           14
                                      All costs excluding biologics   50           41           34           42
  Ever received a biologic (n=225)    Health practitioners            8            7            5            7
                                      Medical acts                    4            2            2            3
                                      Hospitalisations                6            5            3            5
                                      Biologics                       67           74           81           74
                                      All drugs                       69           75           82           76
                                      Productivity loss               13           10           7            10
                                      All costs excluding biologics   33           26           19           26
  Never received a biologic (n=483)   Health practitioners            33           29           29           31
  Medical acts                        9                               8            9            9            
  Hospitalisations                    22                              26           32           26           
  Biologics                           0                               0            0            0            
  All drugs                           8                               7            8            7            
  Productivity loss                   28                              29           22           27           
  All costs excluding biologics       100                             100          100          100          

Health practitioner visits, the second largest cost component of health resource utilisation in all years, declined from €733.2±788.9 in year 1 to €615.0±783.4 in year 2 and €481.0±676.2 in year 3. Hospitalisation costs were incurred by a quarter to a fifth of patients, representing under 10% of costs in each year. The mean hospitalisation cost per patient was €498.4±1318.9 in year 1, €526.2±1325.7 in year 2 and €423.3±1100.8 in year 3. Medical workups were consistently the smallest component of health resource utilisation, never exceeding 5% of yearly costs.

### Productivity losses {#s3b2}

Approximately a third of patients (30.1%) incurred productivity losses in year 1; this decreased to a quarter of patients in year 2 (23.4%) and year 3 (24.4%). The mean cost of productivity losses was €843.4±2899.1 in year 1, €768.9±3368.0 and €497.0±1951.0 in year 3. In year 1, productivity losses represented 16.8% of total costs, compared to 14.1% of total costs in year 2 and 10.0% of total costs in year 3.

### Total costs {#s3b3}

The mean annual total cost per patient was €5004.1±6870.2 in year 1, €5444.1±7936.9 in year 2 and €4960.6±7457.4 in year 3. Mean annual total costs rose with biologic use: patients who did not receive a biologic had mean total costs of €1867.9±3056.6 in year 1, €1628.2±3090.3 in year 2 and €1292.9±2059.6 in year 3, compared to €11 736.4±7882.6 in year 1, €13 635.4±8915.1 in year 2 and €12 833.9±8667.4 in year 3 among patients who received a biologic. In all years, biologics represented over 50% of total costs, up to 66.3% in year 3. Overall, the mean 3-year total cost among patients was €15 408.7±19 793.5. Patients who never received a biologic had mean 3-year total costs of €4789.04±6021.8 compared to €38 205.74±19 829.3 among those who received a biologic. The estimated total costs in the cohort over 3 years amounted to €10 909 399.9±19 574.0. Of this, patients who received a biologic accounted for an estimated €8 596 291.6±4860.9 or 78.8% of all costs in the cohort. [Figure 1](#RMDOPEN2015000230F1){ref-type="fig"} compares the trends in costs over the study period overall and for patients who received and did not receive a biologic.

![Yearly costs among biologics users.](rmdopen2015000230f01){#RMDOPEN2015000230F1}

Factors associated with costs {#s3c}
-----------------------------

### Total costs {#s3c1}

In the final model ([table 3](#RMDOPEN2015000230TB3){ref-type="table"}), each month of biologics use was associated with a 23% increase (rate ratio (RR): 1.23; 95% CI 1.21 to 1.24) in total costs. The presence of peripheral arthritis at baseline was associated with a 19% increase (RR: 1.19; 95% CI 1.04 to 1.37) in total costs, while every 10-point increase in the average BASFI score was associated with an 18% increase in total costs (RR: 1.18; 95% CI 1.15 to 1.22). Although absolute costs were higher in year 2 than year 1 ([table 4](#RMDOPEN2015000230TB4){ref-type="table"}), when adjusting for time on biologics, costs in years 2 and 3 were significantly lower than in year 1 ([table 3](#RMDOPEN2015000230TB3){ref-type="table"}). Imaging status was not significantly associated with total costs and was excluded from the final model ([figure 2](#RMDOPEN2015000230F2){ref-type="fig"}).

###### 

Models of total cost and non-biologic costs

  Outcome                                          Variable                                  Rate ratio (95% CI)   p Value   Estimate   SE       Estimate lower bound   Estimate upper bound   Min. estimate   Max. estimate   Minimum rate ratio   Maximum rate ratio
  ------------------------------------------------ ----------------------------------------- --------------------- --------- ---------- -------- ---------------------- ---------------------- --------------- --------------- -------------------- --------------------
  Total costs                                      Age at baseline (every 5-year increase)   1.06 (1.02 to 1.11)   0.006     0.060      0.022    0.017                  0.102                  0.055           0.065           1.06                 1.07
  Male vs female                                   0.75 (0.65 to 0.87)                       0.000                 −0.287    0.074      −0.432   −0.142                 −0.304                 −0.265          0.74            0.77                 
  Time on biologics (in months)                    1.23 (1.21 to 1.24)                       \<0.0001              0.205     0.005      0.195    0.216                  0.205                  0.205           1.23            1.23                 
  Year 2 vs year 1                                 0.89 (0.78 to 1.01)                       0.063                 −0.119    0.064      −0.244   0.007                  −0.125                 −0.114          0.88            0.89                 
  Year 3 vs year 1                                 0.71 (0.63 to 0.81)                       \<0.0001              −0.339    0.062      −0.462   −0.217                 −0.367                 −0.321          0.69            0.73                 
  Average BASFI score (every 10-point increase)    1.18 (1.15 to 1.22)                       \<0.0001              0.168     0.015      0.137    0.198                  0.164                  0.172           1.18            1.19                 
  Presence of peripheral arthritis at baseline     1.19 (1.04 to 1.37)                       0.014                 0.177     0.072      0.036    0.318                  0.166                  0.198           1.18            1.22                 
  Non-biologic cost*s*                             Age at baseline (every 5-year increase)   1.10 (1.05 to 1.16)   0.000     0.097      0.025    0.047                  0.147                  0.092           0.104           1.10                 1.11
  Male vs female                                   0.69 (0.58 to 0.81)                       \<0.0001              −0.377    0.087      −0.548   −0.206                 −0.398                 −0.349          0.67            0.71                 
  Time on biologics (in months)                    1.04 (1.02 to 1.05)                       \<0.0001              0.037     0.008      0.022    0.052                  0.037                  0.038           1.04            1.04                 
  Year 2 vs year 1                                 0.87 (0.75 to 1.00)                       0.050                 −0.143    0.073      −0.286   0.000                  −0.151                 −0.139          0.86            0.87                 
  Year 3 vs year 1                                 0.72 (0.63 to 0.83)                       \<0.0001              −0.327    0.072      −0.470   −0.184                 −0.357                 −0.301          0.70            0.74                 
  Average BASDAI score (every 10-point increase)   1.21 (1.16 to 1.25)                       \<0.0001              0.187     0.019      0.151    0.224                  0.185                  0.192           1.20            1.21                 
  Presence of peripheral arthritis at baseline     1.20 (1.02 to 1.40)                       0.024                 0.181     0.080      0.024    0.338                  0.170                  0.198           1.18            1.22                 

###### 

Health resource use and productivity loss costs in 2013 Euros by year of follow-up and biologics use

                                                                       Year 1  Year 2   Year 3   Three-year total                                                                                         
  ----------------------------------- ------------------------------- -------- -------- -------- ------------------ ----- -------- ------ -------- ----- -------- ------ -------- ----- -------- -------- --------
  All patients (n=708)                Health practitioners\*             91    733      789      486                 84   615      783    350       77   481      676    254       97   1829     1860     1239
                                      Medical workups†                   79    249      306      144                 71   195      257    85        66   163      234    65        92   607      618      403
                                      Biologics                          24    2515     5322     0                   27   3205     6202   0         26   3287     6460   0         32   9007     16 512   0
                                      All drugs                         100    2680     5340     155                 100  3339     6224   127       100  3396     6477   99        100  9416     16 565   408
                                      HRU costs                         100    4161     5901     1297                100  4675     6780   1107      100  4464     6859   856       100  13 299   17 770   4505
                                      Productivity loss                  30    843      2899     0                   23   769      3368   0         24   497      1951   0         46   2109     5846     0
                                      All costs excluding biologics     100    2489     3629     1228                100  2239     4159   872       100  1673     2718   706       100  6402     7770     3708
                                      All costs                         100    5004     6870     1547                100  5444     7937   1287      100  4961     7457   1063      100  15 409   19 794   5358
  Ever received a biologic (n=225)    Health practitioners\*             99    997      886      722                 94   909      922    577       86   702      886    399       100  2608     2175     1952
                                      Medical workups†                   96    427      374      324                 91   328      303    245       83   265      296    168       100  1020     716      922
                                      Biologics                          76    7913     6819     8510                86   10 084   7191   12 047    81   10 344   7641   12 694    100  28 341   17 606   28 554
                                      All drugs                         100    8123     6802     8548                100  10 265   7183   12 186    100  10 477   7650   12 716    100  28 865   17 568   28 962
                                      HRU costs                         100    10 214   7073     11 175              100  12 244   7422   13 437    100  11 889   7895   13 577    100  34 347   17 833   36 107
                                      Productivity loss                  41    1523     3723     0                   33   1391     4827   0         34   945      2900   0         59   3859     8071     485
                                      All costs excluding biologics     100    3823     4341     2019                100  3552     5614   1677      100  2490     3635   1217      100  9865     9727     6701
                                      All costs                         100    11 736   7883     12 477              100  13 635   8915   13 880    100  12 834   8667   13 765    100  38 206   19 829   39 306
  Never received a biologic (n=483)   Health practitioners\*             88    610      707      352                 80   478      668    211       72   378      522    177       95   1466     1566     937
                                      Medical workups†                   70    166      225      81                  62   132      205    41        59   116      180    41        88   414      452      270
                                      Biologics                          0     0        0        0                    0   0        0      0          0   0        0      0          0   0        0        0
                                      All drugs                         100    145      223      99                  100  113      143    75        100  98       145    53        100  355      423      252
                                      HRU costs                         100    1341     1662     750                 100  1149     1619   510       100  1004     1518   429       100  3495     3501     2240
                                      Productivity loss                  25    527      2360     0                   19   479      2355   0         20   288      1241   0         40   1294     4206     0
                                      All costs excluding biologics     100    1868     3057     850                 100  1628     3090   566       100  1293     2060   521       100  4789     6022     2633
                                      All costs                         100    1868     3057     850                 100  1628     3090   566       100  1293     2060   521       100  4789     6022     2633

\*Health practitioners include physicians and other allied health professionals (nurse, physiotherapist, osteopath, etc).

†Medical workups include blood and urine tests, X-ray, ultrasound, scanner, MRI, bone densitometry, scintigraphy, respirometry, colonoscopy, mammography and fibroscopy.

![Yearly costs among non-biologics users.](rmdopen2015000230f02){#RMDOPEN2015000230F2}

### Cost excluding biologics {#s3c2}

In the final model ([table 3](#RMDOPEN2015000230TB3){ref-type="table"}), each month of biologics use was associated with a 4% increase (RR: 1.04; 95% CI 1.02 to 1.05) in non-biologic costs. The presence of peripheral arthritis at baseline was associated with a 20% increase (RR: 1.20; 95% CI 1.02, 1.40) in non-biologics costs; every 10-point increase in the average BASDAI score was associated with a 21% increase in non-biologic costs (RR: 1.21; 95% CI 1.16 to 1.25). Every 5-year increase in age was associated with a 10% increase (RR: 1.10; 95% CI 1.05 to 1.16) in non-biologic costs, while males had 31% less costs relative to females (RR: 0.69; 95% 0.58 to 0.81). Imaging status was not significantly associated with costs excluding biologics and was excluded from the final model.

Discussion {#s4}
==========

This study described costs related to health resource utilisation and work productivity losses among patients with early SpA over 3 years. Our findings reflect the cost impact of biologics, which represented by far the largest cost component among DESIR patients. In the prebiologic era among patients with AS, work productivity loss was observed to account for the majority of total costs, for example, from 62% of total annual costs among patients with AS in Hong Kong[@R24] to 74% of total annual costs among patients with AS in the UK.[@R25] In our study, an analysis of patients with early SpA in the biologic era, productivity loss may be expected to represent a lower proportion of costs given patients\' better functional status and higher drug costs; that said, productivity loss costs among DESIR patients still represented between 10% and 17% of annual costs over the study period. In terms of absolute costs, work productivity loss costs among DESIR patients (which ranged from €843 in year one to €497 in year 3) are consistent with those in a Dutch cohort of patients with early SpA (approximately €422 over 1 year).[@R26] We note that our estimates of productivity loss costs are conservative: we did not calculate the costs of presenteeism, that is, the cost of reduced performance at work, which is another potentially important source of costs.[@R27]

Currently, there is increased interest in non-radiographic axial SpA, defined as SpA in the absence of definite sacroiliac changes on X-ray, which includes both patients who satisfy only the clinical criteria for SpA and those with active inflammation in the sacroiliac joints visible only on MRI.[@R28] To the best of our knowledge, this is the first longitudinal study of patients with SpA that has explored the impact of radiographic damage on cost, distinguishing between damage on X-Ray with or without MRI inflammation. Interestingly, while preventing progression to radiographic SpA remains a high priority from the clinical perspective, we found no significant independent effect of imaging status on total costs or costs excluding biologics.

In this study, the most significant cost component was biologic drugs, and patients who ever received a biologic accounted for over 75% of total costs in the cohort. While this was not surprising, the finding that approximately a quarter of DESIR patients had received a biologic by the 6-month visit (biologics use at baseline was not permitted[@R9]) was higher than anticipated, suggesting that biologics use was already relatively common even among patients with early SpA in 2010. Whether biologics provide good value for money is being explored in a separate study, which considers the impact of biologics on health-related quality of life. Our study also found peripheral arthritis, age and functional ability to be related to total costs, indicating subgroups where biologic use may be prioritised. In this study, we found that, in the first 3 years, treatment with biologics leads to increased costs in other health resource use domains, not a reduction as is sometimes expected; follow-up is needed to determine whether this trend holds over a longer period.

This study has some limitations. The DESIR cohort includes only patients with early SpA in France between 2007 and 2014; the results cannot necessarily be generalised to patients with SpA with more advanced disease or in other settings at other times. Indeed, it is unknown whether similarly high rates of biologic use exist among patients with early SpA in other countries; another recently established early SpA cohort ('SPACE') is ongoing in the Netherlands,[@R29] but to the best of our knowledge the prevalence of biologics use in this cohort has not as yet been reported. A recent Canadian study of patients with SpA seen clinically between 2003 and 2014 found that 48% had been treated with a biologic, yet the mean disease duration (8 years) was much longer in this sample than in DESIR.[@R30] Generalisable to patients with early SpA in France, our findings will allow for future comparisons with other cohorts of patients with early SpA, as well as the observation of trends within DESIR over time.

In terms of costing methods employed, we did not include non-SpA-related drugs, transportation or presenteeism, or include other patient out-of-pocket costs. Attendance declined over time and data imputation was required. Resource utilisation was self-reported and the potential exists for either underreported or overreported utilisation. In order to exclude the excess resource utilisation associated with study participation, we excluded the baseline visit from cost estimates. However, study participation could have also resulted in underestimation of resource utilisation following the baseline visit, if study visits replaced normal resource utilisation but were not reported as such. Finally, work productivity losses were estimated using self-reported workdays lost (rather than hours lost) and average daily wages by professional category, estimated from the entire population of French workers. We used profession-specific daily wages and did not further adjust wages for age and sex, although there are small differences in the age and sex distribution in DESIR compared to the French working population from which income data were derived (48% female and 77% aged 25--54 among French workers vs 54% female and 81% aged 25--54 in DESIR[@R31]). By not adjusting for the 6% higher proportion of females in DESIR, it could be argued that we have slightly overvalued productivity losses, as daily wages among females in France are lower than among males; however, we note that wage inequality functions more generally to minimise the value of productivity loss. Although our valuation method provides a good estimate of productivity losses, we acknowledge that a greater level of accuracy could be achieved with direct self-report data on wage and productivity losses expressed in hourly terms. Despite these limitations, our findings are consistent with another recent description of patients with early SpA[@R26] and reflect patterns of health resource utilisation and work productivity loss within one of the largest early SpA cohorts to date.
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